drugset / Trial / NCT02457286

Improving Insulin Resistance To Treat Non-Alcoholic Fatty Liver Disease: A Pilot Study

NCT02457286 ↗

Phase 1 Withdrawn Northwell Health
RandomizedParallel-groupOpen-labelTreatment

Summary

Metformin is being compared to exercise and diet modifications. The researchers are interested in learning if the addition of metformin to lifestyle modifications is more helpful in treating the condition or disorder. Although metformin is FDA approved to treat type 2 diabetes, it is not FDA approved for the treatment of Non-alcoholic fatty liver (NAFLD) and is considered investigational for the purpose of this study.

Timeline

Start
2015-06
Primary completion
2017-07
Completion
2017-07

Outcome

Outcome not reported

Stopped: “patients do not want to participate”

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Metformin Small molecule — —

Indications